The idea of using monoclonal antibodies to target RE-derived TAAs emerged from a study conducted by Wang-Johanning et al. As proof of concept, the authors demonstrated that monoclonal antibodies targeting the HERV-K envelope protein reduced the proliferation of breast cancer cells in vitro and significantly reduced tumor growth in mice [217]. Here, ERVW-1 is linked to neoplasm.